These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26732779)

  • 1. QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens.
    Alqahtani QM; Crowley A; Rapp S; Cushman-Vokoun AM
    Lab Med; 2016 Feb; 47(1):30-8. PubMed ID: 26732779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
    Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
    Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.
    Adams JA; Post KM; Bilbo SA; Wang X; Sen JD; Cornwell AJ; Malek AJ; Cheng L
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):231-5. PubMed ID: 24614151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
    Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
    BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
    Mack E; Stabla K; Riera-Knorrenschild J; Moll R; Neubauer A; Brendel C
    BMC Cancer; 2016 Aug; 16():585. PubMed ID: 27485514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
    De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P
    Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.
    Yoshino T; Muro K; Yamaguchi K; Nishina T; Denda T; Kudo T; Okamoto W; Taniguchi H; Akagi K; Kajiwara T; Hironaka S; Satoh T
    EBioMedicine; 2015 Apr; 2(4):317-23. PubMed ID: 26137573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
    de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
    Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
    Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
    J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
    Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
    Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    Darwanto A; Hein AM; Strauss S; Kong Y; Sheridan A; Richards D; Lader E; Ngowe M; Pelletier T; Adams D; Ricker A; Patel N; Kühne A; Hughes S; Shiffman D; Zimmermann D; Te Kaat K; Rothmann T
    BMC Cancer; 2017 May; 17(1):358. PubMed ID: 28532404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation.
    Gao J; Li YY; Sun PN; Shen L
    World J Gastroenterol; 2010 Oct; 16(38):4858-64. PubMed ID: 20939116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and extensive analytical validation of deep amplicon sequencing for detecting KRAS and NRAS mutations in metastatic colorectal cancer samples.
    Slavkovský R; Stránská J; Věnsková V; Jančik S; Kotková L; Šimová J; Vojta P; Flodr P; Bartoušková M; Študentová H; Hajdúch M; Drábek J
    Neoplasma; 2022 Jan; 69(1):203-215. PubMed ID: 34881628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
    Weyn C; Van Raemdonck S; Dendooven R; Maes V; Zwaenepoel K; Lambin S; Pauwels P
    BMC Cancer; 2017 Feb; 17(1):139. PubMed ID: 28201998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.
    Sakai K; Yoneshige A; Ito A; Ueda Y; Kondo S; Nobumasa H; Fujita Y; Togashi Y; Terashima M; De Velasco MA; Tomida S; Nishio K
    Springerplus; 2015; 4(1):7. PubMed ID: 25674493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
    Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
    PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
    Carotenuto P; Roma C; Rachiglio AM; Tatangelo F; Pinto C; Ciardiello F; Nappi O; Iaffaioli RV; Botti G; Normanno N
    Pharmacogenomics; 2010 Aug; 11(8):1169-79. PubMed ID: 20712532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
    Netzel BC; Grebe SK
    Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.